DRRD delivered a strong performance led by the volume growth and new product launches across these markets. We expect revenue and PAT CAGR of 10.3% and 29.3% respectively over the period FY21-FY24E and we recommend a BUY with TP of INR 6,000/share, implying an upside of 11%.